29Y.F - Spexis AG

Frankfurt - Frankfurt Delayed Price. Currency in EUR
10.18
0.00 (0.00%)
At close: 03:43PM CEST
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close10.18
Open0.00
Bid9.97 x N/A
Ask10.26 x N/A
Day's Range0.00 - 0.00
52 Week Range
Volume80
Avg. Volume0
Market Cap117.644M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 29Y.F

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances demonstrating potent in vitro and in vivo antimicrobial activity against MDR and XDR Enterobacteriaceae, including carbapenem-resistant and colistin-resistant strains

      Novel antibiotics were developed by Spexis in close collaboration with Professor Oliver Zerbe’s group at the University of Zurich with substantial funding by Innosuisse and CARB-XALLSCHWIL, Switzerland, June 06, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced the publication of preclinical results from the company’s novel class of macrocyclic, peptidomimetic antibiotics developed in collaboration wi

    • GlobeNewswire

      Spexis provides business update and announces financial results for the full year 2022

      Ad hoc announcement pursuant to Art. 53 LR USD 4.5 million capital commitment from SPRIM Global Investments to enable initiation of ColiFin® COPILOT study; first patient dosing expected in mid-2023Reported solid safety and pharmacokinetics results from first-in-human study of inhaled murepavadinAnnounced positive renal impairment clinical trial results with balixafortide ALLSCHWIL, Switzerland, May 29, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company foc

    • GlobeNewswire

      Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study

      Ad hoc announcement pursuant to Art. 53 LR Funding to enable immediate initiation of the COPILOT study, the first of two Phase 3 ColiFin® studies; first-patient-in expected in June 2023Commitment structured as a mix of secured debt and subordinated debt mandatorily converting into equity ALLSCHWIL, Switzerland, April 18, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has finalized

    • GlobeNewswire

      Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin®

      Ad hoc announcement pursuant to Art. 53 LR SGI debt facility to provide Spexis up to half of the projected ColiFin® Phase 3 development costs, including those involving both COPILOT and COPASGI has invested in Spexis as part of the ColiFin® P3 clinical trial partnership financing; additional investments from other investors expected in the near futureSGI debt facility subject to a number of conditions, including negotiation of final agreements ALLSCHWIL, Switzerland, Feb. 08, 2023 (GLOBE NEWSWIR

    • GlobeNewswire

      Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound

      Ad hoc announcement pursuant to Art. 53 LR Inhaled murepavadin shown to be well tolerated at all dose levels Program derived from Spexis’ macrocycle platformData support moving forward to Phase 2 in cystic fibrosis and non-cystic fibrosis bronchiectasis lung infection ALLSCHWIL, Switzerland, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced the successful completion of the first-in-human clin

    • GlobeNewswire

      Spexis announces promising pre-clinical data with balixafortide in combination with various therapies on the market for treating B-cell lymphomas

      Balixafortide shown to have synergistic or additive effect with conventional or targeted therapies across all tested B-cell lymphomas ALLSCHWIL, Switzerland, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced results from an in vitro study evaluating the effects of combining Spexis’ potent CXCR4 inhibitor balixafortide (BLX) with several conventional or targeted therapies on the market in B-ce

    • GlobeNewswire

      Spexis announces positive renal impairment clinical trial results with balixafortide

      Phase 1 clinical trial in patients with renal impairment demonstrates balixafortide to be safe and well tolerated Safety findings support potential to use significantly higher doses of balixafortide than those previously investigatedAdditional observations indicate potential for stimulating prolonged stem cell mobilization, a potentially key advantage in implementing hematopoietic stem cell transplantation ALLSCHWIL, Switzerland, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinic

    • GlobeNewswire

      Spexis provides business update and announces financial results for the first half of 2022

      Ad hoc announcement pursuant to Art. 53 LR Study start-up activities nearly complete for COPILOT, the first part of the Phase 3 ColiFin® program, including regulatory and ethics committee approvals of trial sites Enrollment of Phase 1 trial of inhaled murepavadin in healthy volunteers continues with top-line results expected by year-end 2022Analysis of balixafortide PK/safety clinical trial in renally impaired subjects completed; results expected to be announced this fall Good progress in earlie

    • GlobeNewswire

      Spexis announces presentation of half-year 2022 financial results and participation at upcoming industry and investor events in September

      ALLSCHWIL, Switzerland, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company will hold a live call and webcast to discuss its half-year 2022 financial results and provide a business update on September 6, 2022, 8am ET / 2pm CET. To participate, please use the following numbers:France:+33 (0)1 70 730 3 39Germany:+49 (0)69 22222 5197Italy:+39 0200638217Switzerland:+41 (0)44 580 72

    • GlobeNewswire

      Spexis provides business update

      Ad hoc announcement pursuant to Art. 53 LRCash position to finance operations extended into January 2023Resources focused on advancing lead program, Phase 3 ColiFin®Assessment of balixafortide development options continues; balixafortide PK/safety clinical trial in renally impaired subjects completed; results expected to be reported this fallProgress in earlier-stage pipeline derived from macrocycle platformVariety of partnering and funding options being vigorously exploredCompany renews equity-

    • GlobeNewswire

      Spexis announces business update call to be held on July 28th

      Conference call scheduled for Thursday, July 28, 2022, at 8 AM EDT / 2 PM CETALLSCHWIL, Switzerland, July 20, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX) a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company will hold a business update call on Thursday, July 28, 2022, at 8 AM EDT / 2 PM CET. To participate, please use the following numbers: France: +33 (0)1 70 730 3 39Germany: +49 (0)69 22222 5197Italy: +39 0200638217Switzerland: +4

    • GlobeNewswire

      Spexis' CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical model

      ALLSCHWIL, Switzerland, July 07, 2022 (GLOBE NEWSWIRE) -- SPEXIS AG (SIX: SPEX), a clinical-stage biopharmaceutical company, today announced that its CXCR4 inhibitor balixafortide demonstrated synergistic efficacy in combination with docetaxel compared to either drug alone in a metastatic prostate cancer preclinical model. Balixafortide is a potent and selective clinical-stage CXCR4 inhibitor. Spexis is currently evaluating various development opportunities for this program, including in hematol